Orphanet: Ricerca per farmaco orfano
x

Cerca un farmaco orfano

* (*) campo obbligatorio

Altra/e opzione/i di ricerca

Ritiro dell’autorizzazione alla commercializzazione - Europa

  • denominazione commerciale: IMATINIB TEVA B.V.
  • Codice ATC : L01XE01
  • Numero EU: EU/1/17/1243
  • AIC data : 15/11/2017
  • Titolare dell'AIC: TEVA PHARMACEUTICALS EUROPE B.V.

Therapeutic indication

Imatinib Teva B.V. is indicated for the treatment of:
* Paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
* Paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
* Adult patients with Ph+ CML in blast crisis.
* Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
* Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
* Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
* Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
The effect of imatinib on the outcome of bone marrow transplantation has not been determined.

Imatinib Teva B.V. is indicated for:
* The treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
* The adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.
* The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

Tutte le informazioni presenti nel sito non sostituiscono in alcun modo il giudizio di un medico specialista, l'unico autorizzato ad effettuare una consulenza medica ed esprimere un parere medico.